Wednesday, CytomX Therapeutics Inc CTMX launched preliminary knowledge from the continuing CX-904 Part 1a dose escalation medical examine, demonstrating a positive security profile and confirmed anti-cancer exercise.
As of April 16, 2024, knowledge cutoff, the Part 1 examine enrolled 35 closely pretreated sufferers with superior metastatic stable tumor sorts.
CX-904 demonstrated a positive security profile, supporting administration and monitoring enrolled sufferers in an outpatient setting.
Eight sufferers had measurable tumor discount at knowledge cutoff, together with 2 of 6 efficacy-evaluable sufferers (33%) with pancreatic most cancers with confirmed partial responses.
All six efficacy-evaluable sufferers with pancreatic most cancers achieved illness management (goal response or steady illness).
One affected person (6 mg goal dose) achieved an 83% tumor discount for the 2 sufferers with a confirmed partial response.
The second affected person (5 mg goal dose) with a confirmed response achieved a 51% tumor discount and remained on examine remedy.
Third pancreatic most cancers affected person maintained steady illness with no proof of tumor progress by way of 3.5 months of examine remedy and remained on remedy as of the information cutoff.
The corporate expects to offer an extra Part 1a dose escalation replace by the tip of 2024.
Wednesday, CytomX Therapeutics reported first-quarter EPS of $0.17 in comparison with $(0.05) a 12 months in the past, beating the consensus of $(0.06)
Gross sales elevated from $23.5 million to $41.46 million.
Wedbush upgraded CytomX Therapeutics to Outperform from Impartial, noting extra promising validation of the masking know-how for T-cell engager (TCEs) (>10 partnered analysis applications are centered in TCEs) and development of the medical pipeline applications.
The analyst elevated the value goal from $3 to $8 with added potential CX-904 revenues for pancreatic most cancers.
H.C. Wainwright notes that the detrimental inventory response is probably going because of the presentation of the respective tumor sorts and dose ranges the place tumor regressions had been noticed.
“Whereas we consider the dataset in pancreatic most cancers appears to be like most encouraging, this can be a subtype that has traditionally confronted quite a few medical challenges, resulting in setbacks for different biotech companies—as such, we want to see a broader pancreatic most cancers dataset to turn into extra comfy on this indication,” H.C. Wainwright provides.
In different subtypes, the analyst awaits additional knowledge to see proof of traits by tumor sort and dose stage. It reiterates a Impartial score with out a value goal.
Worth Motion: CTMX shares are down 46.1% at $2.259 ultimately test Thursday.
Picture by PDPics from Pixabay
